263 related articles for article (PubMed ID: 36672509)
1. Patient-Derived Organoids: The Beginning of a New Era in Ovarian Cancer Disease Modeling and Drug Sensitivity Testing.
Psilopatis I; Sykaras AG; Mandrakis G; Vrettou K; Theocharis S
Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672509
[TBL] [Abstract][Full Text] [Related]
2. Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models.
Maenhoudt N; Defraye C; Boretto M; Jan Z; Heremans R; Boeckx B; Hermans F; Arijs I; Cox B; Van Nieuwenhuysen E; Vergote I; Van Rompuy AS; Lambrechts D; Timmerman D; Vankelecom H
Stem Cell Reports; 2020 Apr; 14(4):717-729. PubMed ID: 32243841
[TBL] [Abstract][Full Text] [Related]
3. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine.
Nero C; Vizzielli G; Lorusso D; Cesari E; Daniele G; Loverro M; Scambia G; Sette C
J Exp Clin Cancer Res; 2021 Mar; 40(1):116. PubMed ID: 33789687
[TBL] [Abstract][Full Text] [Related]
4. An experimental model for ovarian cancer: propagation of ovarian cancer initiating cells and generation of ovarian cancer organoids.
Chen YA; Lu CY; Cheng WF; Kuo KT; Yu CW; Ho HN; Chen HF; Pan SH
BMC Cancer; 2022 Sep; 22(1):967. PubMed ID: 36085021
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived organoids in ovarian cancer: Current research and its clinical relevance.
Kumar S; Raina M; Tankay K; Ingle GM
Biochem Pharmacol; 2023 Jul; 213():115589. PubMed ID: 37196684
[TBL] [Abstract][Full Text] [Related]
6. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
Chen H; Gotimer K; De Souza C; Tepper CG; Karnezis AN; Leiserowitz GS; Chien J; Smith LH
Gynecol Oncol; 2020 Jun; 157(3):783-792. PubMed ID: 32253045
[TBL] [Abstract][Full Text] [Related]
7. Application of Ovarian Cancer Organoids in Precision Medicine: Key Challenges and Current Opportunities.
Yang J; Huang S; Cheng S; Jin Y; Zhang N; Wang Y
Front Cell Dev Biol; 2021; 9():701429. PubMed ID: 34409036
[TBL] [Abstract][Full Text] [Related]
8. Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine.
Spagnol G; Sensi F; De Tommasi O; Marchetti M; Bonaldo G; Xhindoli L; Noventa M; Agostini M; Tozzi R; Saccardi C
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046719
[TBL] [Abstract][Full Text] [Related]
9. Primary human organoids models: Current progress and key milestones.
Calà G; Sina B; De Coppi P; Giobbe GG; Gerli MFM
Front Bioeng Biotechnol; 2023; 11():1058970. PubMed ID: 36959902
[TBL] [Abstract][Full Text] [Related]
10. The Role of Patient-Derived Organoids in Triple-Negative Breast Cancer Drug Screening.
Psilopatis I; Mantzari A; Vrettou K; Theocharis S
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979752
[TBL] [Abstract][Full Text] [Related]
11. Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment.
Hu H; Sun C; Chen J; Li Z
J Cancer Res Clin Oncol; 2024 Mar; 150(3):146. PubMed ID: 38509422
[TBL] [Abstract][Full Text] [Related]
12. Experimental models for ovarian cancer research.
Tsang SI; Hassan AA; To SKY; Wong AST
Exp Cell Res; 2022 Jul; 416(1):113150. PubMed ID: 35405118
[TBL] [Abstract][Full Text] [Related]
13. Harnessing preclinical models for the interrogation of ovarian cancer.
Qin T; Fan J; Lu F; Zhang L; Liu C; Xiong Q; Zhao Y; Chen G; Sun C
J Exp Clin Cancer Res; 2022 Sep; 41(1):277. PubMed ID: 36114548
[TBL] [Abstract][Full Text] [Related]
14. Current Status of Patient-Derived Ovarian Cancer Models.
Maru Y; Hippo Y
Cells; 2019 May; 8(5):. PubMed ID: 31130643
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.
Nanki Y; Chiyoda T; Hirasawa A; Ookubo A; Itoh M; Ueno M; Akahane T; Kameyama K; Yamagami W; Kataoka F; Aoki D
Sci Rep; 2020 Jul; 10(1):12581. PubMed ID: 32724113
[TBL] [Abstract][Full Text] [Related]
16. Protocol for establishing organoids from human ovarian cancer biopsies.
Maenhoudt N; Vankelecom H
STAR Protoc; 2021 Jun; 2(2):100429. PubMed ID: 33870230
[TBL] [Abstract][Full Text] [Related]
17. Organoids: A New Chapter in Sarcoma Diagnosis and Treatment.
Psilopatis I; Kokkali S; Palamaris K; Digklia A; Vrettou K; Theocharis S
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232574
[TBL] [Abstract][Full Text] [Related]
18. Using genetically encoded fluorescent biosensors to interrogate ovarian cancer metabolism.
Bose S; Yao H; Huang Q; Whitaker R; Kontos CD; Previs RA; Shen X
J Ovarian Res; 2022 Oct; 15(1):114. PubMed ID: 36266675
[TBL] [Abstract][Full Text] [Related]
19. Concise Review: Current Status of Three-Dimensional Organoids as Preclinical Models.
Kaushik G; Ponnusamy MP; Batra SK
Stem Cells; 2018 Sep; 36(9):1329-1340. PubMed ID: 29770526
[TBL] [Abstract][Full Text] [Related]
20. Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing.
Bi J; Newtson AM; Zhang Y; Devor EJ; Samuelson MI; Thiel KW; Leslie KK
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34200645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
